Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Mixed and Match vs One-size-fits-all

22 mars 2022 mis à jour par: Dr Katherine Lam, The Hong Kong Polytechnic University

Mixed and Match Versus One-size-fits-all: A Randomized Controlled Trial of Self-determination Theory on a Menu of Smoking Cessation Options (SDTM) Among Adult Smokers

Most existing smoking cessation services are based on '5A's' and '5R's' models which are recognized by the World Health Organization as a standardized tool for smoking cessation. While there are more techniques that are known to be effective and could be incorporated in existing smoking cessation interventions to further promote their effectiveness. This study is to examine the effectiveness SDTM in assisting adult smokers in Hong Kong to quit.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Description détaillée

A randomized controlled trial (RCT) will be conducted. One-hundred adult smokers aged 25 or above will be recruited from smoking hotspots in Hong Kong. Participants in the intervention group will be contacted by our trained research assistant to receive a telephone counselling session at baseline. Participants can choose to receive their own smoking cessation treatment options from our menu. Control group participants will only receive a self-help quitting leaflet

Type d'étude

Interventionnel

Inscription (Anticipé)

500

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

25 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • have smoking in the previous 30 days.
  • be above 25 years old
  • able to speak Cantonese and read Chinese

Exclusion Criteria:

  • who are receiving current smoking cessation services
  • report psychological disorders
  • at risk of suicide

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Autre: Mixed and Match
Participants can choose to receive their own smoking cessation treatment options from our menu.
Participants will receive a brief 15-minute counselling session based on the 5A's' and '5R's' models by our trained research assistant. Participants will be able to choose their smoking cessation treatment options from our menu.
Autre: Control
Participants will receive a self-help quitting leaflet
Participants in the control group will receive a self-help quitting leaflet issued by the TACO

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Self-reported abstinence at 6-month follow-up
Délai: At 6-month follow-up
participants will be asked about their self-reported abstinence in the past 7 and 30 days
At 6-month follow-up
Biochemically validated abstinence
Délai: At 6 months follow-up
validate the self-reported abstinence if the level of carbon monoxide in expired air was less than 4 parts per million and saliva cotinine level was less than100 ng/mL in parallel tests
At 6 months follow-up
Self-efficacy at 6-month follow-up
Délai: At 6-month follow-up
Participants will be asked about their self-efficacy in quitting. The score ranges from 0 to 10. Higher scores represent a higher self-efficacy.
At 6-month follow-up

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Screening rate
Délai: at day 1
calculated as the number of smokers screened at smoking hotspots by the RA divided by number of smokers available
at day 1
Eligibility rate
Délai: at day 1
calculated by dividing the number of smokers who are eligible by the number who are screened.
at day 1
Randomization rate
Délai: at day 1
calculated by dividing the number of smokers who are randomized into intervention and control groups by those who provide consent.
at day 1
Attendance rate
Délai: Immediately after the training workshop
calculated by dividing the number of smokers who complete the intervention by those who are randomized.
Immediately after the training workshop
Retention rate at 1-week follow-up
Délai: At 1-week follow-up
calculated by dividing the number of smokers who remain in the study by those who are randomized
At 1-week follow-up
Retention rate at 1-month follow-up
Délai: At 1-month follow-up
calculated by dividing the number of smokers who remain in the study by those who are randomized
At 1-month follow-up
Retention rate at 6-month follow-up
Délai: At 6-month follow-up
calculated by dividing the number of smokers who remain in the study by those who are randomized
At 6-month follow-up
Retention rate at 3-month follow-up
Délai: At 3-month follow-up
calculated by dividing the number of smokers who remain in the study by those who are randomized
At 3-month follow-up
Adherence to intervention protocol at 1-week follow-up
Délai: At 1-week follow-up
calculated by dividing the number of smokers who follow and practice the chosen treatment options by those who are randomized
At 1-week follow-up
Adherence to intervention protocol at 1-month follow-up
Délai: At 1-month follow-up
calculated by dividing the number of smokers who follow and practice the chosen treatment options by those who are randomized
At 1-month follow-up
Adherence to intervention protocol at 3-month follow-up
Délai: At 3-month follow-up
calculated by dividing the number of smokers who follow and practice the chosen treatment options by those who are randomized
At 3-month follow-up
Adherence to intervention protocol at 6-month follow-up
Délai: At 6-month follow-up
calculated by dividing the number of smokers who follow and practice the chosen treatment options by those who are randomized
At 6-month follow-up
Complete rate at 1-week follow-up
Délai: At 1-week follow-up
calculated by dividing the number of smokers who returned questionnaires by the number of questionnaires distributed
At 1-week follow-up
Complete rate at 1-month follow-up
Délai: At 1-month follow-up
calculated by dividing the number of smokers who returned questionnaires by the number of questionnaires distributed
At 1-month follow-up
Complete rate at 3-month follow-up
Délai: At 3-month follow-up
calculated by dividing the number of smokers who returned questionnaires by the number of questionnaires distributed
At 3-month follow-up
Complete rate at 6-month follow-up
Délai: At 6-month follow-up
calculated by dividing the number of smokers who returned questionnaires by the number of questionnaires distributed
At 6-month follow-up
Missing data at 1-week follow-up
Délai: At 1-week follow-up
calculated as the percentage of missing values in the dataset
At 1-week follow-up
Missing data at 1-month follow-up
Délai: At 1-month follow-up
calculated as the percentage of missing values in the dataset
At 1-month follow-up
Missing data at 3-month follow-up
Délai: At 3-month follow-up
calculated as the percentage of missing values in the dataset
At 3-month follow-up
Missing data at 6-month follow-up
Délai: At 6-month follow-up
calculated as the percentage of missing values in the dataset
At 6-month follow-up
Adverse events at 6-month follow-up
Délai: At 6-month follow-up
Participants will report any unfavorable and unintended events
At 6-month follow-up
Adverse events at 1-week follow-up
Délai: At 1-week follow-up
Participants will report any unfavorable and unintended events
At 1-week follow-up
Adverse events at 1-month follow-up
Délai: At 1-month follow-up
Participants will report any unfavorable and unintended events
At 1-month follow-up
Adverse events at 3-month follow-up
Délai: At 3-month follow-up
Participants will report any unfavorable and unintended events
At 3-month follow-up
Self-reported abstinence at 1-week follow-up
Délai: At 1-week follow-up
Participants will be asked about their self-reported abstinence in the past 7 and 30 days
At 1-week follow-up
Self-reported abstinence at 1-month follow-up
Délai: At 1-month follow-up
participants will be asked about their self-reported abstinence in the past 7 and 30 days
At 1-month follow-up
Self-reported abstinence at 3-month follow-up
Délai: At 3-month follow-up
participants will be asked about their self-reported abstinence in the past 7 and 30 days
At 3-month follow-up
Self-efficacy at 1-week follow-up
Délai: at 1-week follow-up
Participants will be asked about their self-efficacy in quitting. The score ranges from 0 to 10. Higher scores represent a higher self-efficacy.
at 1-week follow-up
Self-efficacy at 1-month follow-up
Délai: at 1-month follow-up
Participants will be asked about their self-efficacy in quitting. The score ranges from 0 to 10. Higher scores represent a higher self-efficacy.
at 1-month follow-up
Self-efficacy at 3-month follow-up
Délai: at 3-month follow-up
Participants will be asked about their self-efficacy in quitting. The score ranges from 0 to 10. Higher scores represent a higher self-efficacy.
at 3-month follow-up

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Katherine Lam, PhD, The Hong Kong Polytechnic University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Anticipé)

1 juillet 2022

Achèvement primaire (Anticipé)

31 décembre 2023

Achèvement de l'étude (Anticipé)

31 décembre 2023

Dates d'inscription aux études

Première soumission

18 mai 2021

Première soumission répondant aux critères de contrôle qualité

22 mars 2022

Première publication (Réel)

28 mars 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 mars 2022

Dernière mise à jour soumise répondant aux critères de contrôle qualité

22 mars 2022

Dernière vérification

1 mars 2022

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • SDTM-adult

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Mixed and match Intervention

3
S'abonner